{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:08:15Z","timestamp":1785391695937,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001246","name":"Ambrose Monell Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000771","name":"Prostate Cancer UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000771","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.euf.2025.02.007","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T12:37:54Z","timestamp":1743856674000},"page":"588-594","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Discovery of a Recurrent Frameshift Ashkenazi Jewish Founder Mutation (F722fs) in the PARP Inhibitor\u2013sensitive MMS22L Gene Associated with Higher Risk of Prostate Cancer"],"prefix":"10.1016","volume":"11","author":[{"given":"William B.","family":"Isaacs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Gielzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan A.","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guifang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Engelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Rabizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polina","family":"Sysa-Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Cornell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuqing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huy","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Lupold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwademilade","family":"Dairo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick C.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Helfand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen A.","family":"Cooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2025.02.007_b0005","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jama.2015.17703","article-title":"Familial risk and heritability of cancer among twins in Nordic countries","volume":"315","author":"Mucci","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.euf.2025.02.007_b0010","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41588-020-00748-0","article-title":"Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction","volume":"53","author":"Conti","year":"2021","journal-title":"Nat Genet"},{"key":"10.1016\/j.euf.2025.02.007_b0015","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1038\/s41588-023-01534-4","article-title":"Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants","volume":"55","author":"Wang","year":"2023","journal-title":"Nat Genet"},{"key":"10.1016\/j.euf.2025.02.007_b0020","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1110000","article-title":"Germline mutations in HOXB13 and prostate-cancer risk","volume":"366","author":"Ewing","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2025.02.007_b0025","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2025.02.007_b0030","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"31","author":"Castro","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.02.007_b0035","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.euo.2019.12.003","article-title":"Rare germline pathogenic mutations of DNA repair genes are most strongly associated with grade group 5 prostate cancer","volume":"3","author":"Wu","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2025.02.007_b0040","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/pros.24252","article-title":"Association of germline rare pathogenic mutations in guideline-recommended genes with prostate cancer progression: a meta-analysis","volume":"82","author":"Shi","year":"2022","journal-title":"Prostate"},{"key":"10.1016\/j.euf.2025.02.007_b0045","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.eururo.2020.11.014","article-title":"Performance of three inherited risk measures for predicting prostate cancer incidence and mortality: a population-based prospective analysis","volume":"79","author":"Shi","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.02.007_b0050","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.eururo.2021.04.013","article-title":"Combined effect of a polygenic risk score and rare genetic variants on prostate cancer risk","volume":"80","author":"Darst","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.02.007_b0055","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1200\/JCO.20.00046","article-title":"Implementation of germline testing for prostate cancer: Philadelphia prostate cancer consensus conference 2019","volume":"38","author":"Giri","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.02.007_b0060","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.eururo.2016.08.037","article-title":"DNA repair in prostate cancer: biology and clinical implications","volume":"71","author":"Mateo","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.02.007_b0065","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2025.02.007_b0070","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41467-023-35880-y","article-title":"CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer","volume":"14","author":"Tsujino","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.euf.2025.02.007_b0075","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41391-021-00466-6","article-title":"KLK3 germline mutation I179T complements DNA repair genes for predicting prostate cancer progression","volume":"25","author":"Xu","year":"2022","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.euf.2025.02.007_b0080","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1002\/cncr.30817","article-title":"Germline genetic variants in men with prostate cancer and one or more additional cancers","volume":"123","author":"Pilie","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2025.02.007_b0085","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/pros.24140","article-title":"Association of prostate cancer polygenic risk score with number and laterality of tumor cores in active surveillance patients","volume":"81","author":"Xu","year":"2021","journal-title":"Prostate"},{"key":"10.1016\/j.euf.2025.02.007_b0090","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.euf.2025.02.007_b0095","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41586-018-0579-z","article-title":"The UK Biobank resource with deep phenotyping and genomic data","volume":"562","author":"Bycroft","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.euf.2025.02.007_b0100","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","article-title":"The mutational constraint spectrum quantified from variation in 141,456 humans","volume":"581","author":"Karczewski","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.euf.2025.02.007_b0105","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.ajhg.2017.04.015","article-title":"Evaluating the clinical validity of gene-disease associations: an evidence-based framework developed by the Clinical Genome Resource","volume":"100","author":"Strande","year":"2017","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.euf.2025.02.007_b0110","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3389\/fgene.2014.00187","article-title":"Firth logistic regression for rare variant association tests","volume":"5","author":"Wang","year":"2014","journal-title":"Front Genet"},{"key":"10.1016\/j.euf.2025.02.007_b0115","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/pros.24195","article-title":"Observed evidence for guideline-recommended genes in predicting prostate cancer risk from a large population-based cohort","volume":"81","author":"Wei","year":"2021","journal-title":"Prostate"},{"key":"10.1016\/j.euf.2025.02.007_b0120","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1158\/1055-9965.EPI-09-0058","article-title":"Germ-line mutations in mismatch repair genes associated with prostate cancer","volume":"18","author":"Grindedal","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.euf.2025.02.007_b0125","doi-asserted-by":"crossref","first-page":"4409","DOI":"10.1200\/JCO.2012.43.2278","article-title":"Risks of less common cancers in proven mutation carriers with lynch syndrome","volume":"30","author":"Engel","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.02.007_b0130","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.eururo.2017.04.003","article-title":"The search for the missing heritability of prostate cancer","volume":"72","author":"Walsh","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.02.007_b0135","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.molcel.2010.10.022","article-title":"A genome-wide camptothecin sensitivity screen identifies a mammalian MMS22L-NFKBIL2 complex required for genomic stability","volume":"40","author":"O\u2019Connell","year":"2010","journal-title":"Mol Cell"},{"key":"10.1016\/j.euf.2025.02.007_b0140","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202201596","article-title":"MMS22L-TONSL functions in sister chromatid cohesion in a pathway parallel to DSCC1-RFC","volume":"6","author":"van Schie","year":"2023","journal-title":"Life Sci Alliance"},{"key":"10.1016\/j.euf.2025.02.007_b0145","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.molcel.2018.01.031","article-title":"The histone chaperones ASF1 and CAF-1 promote MMS22L-TONSL-mediated Rad51 loading onto ssDNA during homologous recombination in human cells","volume":"69","author":"Huang","year":"2018","journal-title":"Mol Cell"},{"key":"10.1016\/j.euf.2025.02.007_b0150","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1023\/A:1015575125780","article-title":"Chromosomal deletions and tumor suppressor genes in prostate cancer","volume":"20","author":"Dong","year":"2001","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.euf.2025.02.007_b0155","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/pros.20543","article-title":"DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies","volume":"67","author":"Sun","year":"2007","journal-title":"Prostate"},{"key":"10.1016\/j.euf.2025.02.007_b0160","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.1158\/1078-0432.CCR-07-0300","article-title":"Deletion of a small consensus region at 6q15, including the MAP3K7 gene, is significantly associated with high-grade prostate cancers","volume":"13","author":"Liu","year":"2007","journal-title":"Clin Cancer Res"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925000446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925000446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T18:28:44Z","timestamp":1768760924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456925000446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2405456925000446"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2025.02.007","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of a Recurrent Frameshift Ashkenazi Jewish Founder Mutation (F722fs) in the PARP Inhibitor\u2013sensitive MMS22L Gene Associated with Higher Risk of Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2025.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}